Pioglitazone Increases Gallbladder Volume in Insulin-Resistant Obese Mice

Journal of Surgical Research

Volumn 136, Issue 2, 2006, Pages 192-197

  Al Azzawi, Hayder H ^a   Mathur, Abhishek ^a   Lu, Debao ^a   Swartz Basile, Deborah A ^a   Nakeeb, Attila ^a   Pitt, Henry A ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

diabetes; gallbladder; insulin; insulin resistance; pioglitazone

Indexed keywords

ACETYLCHOLINE; CHOLECYSTOKININ; GLUCOSE; INSULIN; NEUROPEPTIDE Y; NEUROTRANSMITTER; PIOGLITAZONE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLADDER CAPACITY; CARBOHYDRATE DIET; CHOLECYSTECTOMY; COMPARATIVE STUDY; CONTROLLED STUDY; DIET RESTRICTION; FEMALE; GALLBLADDER; GLUCOSE BLOOD LEVEL; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL;

ACETYLCHOLINE; AGE FACTORS; ANIMALS; BLOOD GLUCOSE; CHOLECYSTOKININ; CHOLINERGIC AGENTS; DIETARY CARBOHYDRATES; FEMALE; GALLBLADDER; GALLSTONES; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; LEPTIN; MICE; MICE, INBRED C57BL; MICE, OBESE; NEUROPEPTIDE Y; OBESITY; ORGAN SIZE; PEPTIDE FRAGMENTS; THIAZOLIDINEDIONES;

EID: 33750956901     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2006.06.022     Document Type: Article

References (46)

1. Centers for Disease Control and Prevention. National diabetes fact sheet: General information and national estimates on diabetes in the United States, 2003 (2003), US Dept of Health and Human Services, Centers for Disease Control and Prevention, Atlanta, GA
2. Mokdad A.H., Ford E.S., Bowman B.A., et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 289 (2003) 76
3. Kayacetin E., Kiasakol G., Kaya A., and Akpinar Z. Real-time sonography for screening of gallbladder motility in diabetic patients: Relation to autonomic and peripheral neuropathy. Neuroendocrinol Lett 24 (2003) 73
4. De Santis A., Attili A.F., Ginanni Corradini S., et al. Gallstones and diabetes: A case-control study in a free-living population sample. Hepatology 25 (1997) 787
5. Everhart J.E., Khare M., Hill M., Hill M., and Maurer K.R. Prevalence and ethnic differences in gallbladder disease in the United States. Gastroenterology 117 (1999) 632
6. Tran K.Q., Goldblatt M.I., Swartz-Basile D.A., Svatek C., Nakeeb A., and Pitt H.A. Diabetes and hyperlipidemia correlate with gallbladder contractility in leptin-related murine obesity. J Gastrointest Surg 7 (2003) 857
7. Graewin S.J., Lee K.H., Kiely J.M., Svatek C.L., Nakeeb A., and Pitt H.A. Gallbladder myocytes are short and cholecystokinin-resistant in obese diabetic mice. Surgery 136 (2004) 431
8. Graewin S.J., Tran K.Q., Nuggert J.K., et al. Diminished gallbladder motility in rotund leptin-resistant obese mice. HPB 7 (2005) 139
9. Graewin S.J., Kiely J.M., Svatek C.L., and Pitt H.A. Ciliary neurotrophic factor restores gallbladder contractility in leptin-resistant obese diabetic mice. J Surg Res 130 (2006) 146
10. Nakeeb A., Comuzzie A.G., Al-Azzawi H.H., Sonnenberg G.E., Kissebah A.H., and Pitt H.A. Insulin resistance causes human gallbladder dysmotiligy. J Gastro Surg 10 (2006) 940
11. Hahm J.S., Park J.Y., Park K.G., et al. Gallbladder motility in diabetes mellitus using real time ultrasonography. Am J Gastroenterol 91 (1996) 2391
12. Bowen L., Stein P.P., Stevenson R., and Shulman G.I. The effect of CP 68,722, a thiozolidinedione derivative, on insulin sensitivity in lean and obese Zucker rats. Metabolism 40 (1991) 1025
13. Nolan J.J., Ludvik B., Beerdsen P., Joyce M., and Olefsky J. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 331 (1994) 1188
14. Saltiel A.R. New perspectives into the molecular pathogenesis and treatment of type 2 diabetes. Cell 104 (2001) 517
15. Mauvais-Jarvis F., and Kahn C.R. Understanding the pathogenesis and treatment of insulin resistance and type 2 diabetes mellitus: What can we learn from transgenic and knockout mice?. Diabetes Metab 26 (2000) 433
16. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 351 (2004) 1106
17. Okuno A., Tamemoto H., Tobe K., et al. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest 101 (1998) 1354
18. Evans R.M., Barish G.D., and Wang Y.X. PPARs and the complex journey to obesity. Nat Med 10 (2004) 355
19. Rangwala S.M., and Lazar M.A. Peroxisome proliferator-activated receptor gamma in diabetes and metabolism. Trends Pharmacol Sci 25 (2004) 331
20. Olefsky J.M., and Saltiel A.R. PPAR gamma and the treatment of insulin resistance. Trends Endocrinol Metab 11 (2000) 362
21. Pfutzner A., and Forst T. Pioglitazone: An antidiabetic drug with the potency to reduce cardiovascular mortality. Expert Opin Pharmacother 7 (2006) 463
22. Kubota N., Terauchi Y., Kubota T., et al. Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin dependent and independent pathway. J Biol Chem 281 (2006) 8748
23. Waugh J., Keating G.M., Plosker G.L., Easthope S., and Robinson D.M. Pioglitazone: A review of its use in type 2 diabetes mellitus. Drugs 66 (2006) 85
24. Majali K.A., Cooper M.B., Staels B., Luc G., Taskinen M.R., and Betteridge D.J. The effect of sensitisation to insulin with pioglitazone on fasting and postprandial lipid metabolism, lipoprotein modification by lipases, and lipid transfer activities in type 2 diabetic patients. Diabetologia 49 (2006) 527
25. Mathews D.R., Hosker J.P., Rudenski A.S., Taylor B.A., Treacher D.F., and Turner R.C. Homeostasis model assessment, insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985) 412
26. Wallace T.M., Levy J.C., and Mathews D.R. Use and abuse of HOMA modeling. Diabetes Care 27 (2004) 1487
27. Goldblatt M.I., Swartz-Basile D.A., Svatek C.L., Nakeeb A., and Pitt H.A. Decreased gallbladder response in leptin-deficient obese mice. J Gastrointest Surg 6 (2002) 438
28. Goldblatt M.I., Swartz-Basile D.A., Al-Azzawi H.H., Tran K.Q., Nakeeb A., and Pitt H.A. Nonalcoholic fatty gallbladder disease: The influence of diet in lean and obese mice. J Gastrointest Surg 10 (2006) 193
29. Promrat K., Lutchman G., Uwaifo G.I., et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 39 (2004) 188
30. Gupte P., Amarapurkar D., Agal S., et al. Non-alcoholic steatohepatitis in type 2 diabetes mellitus. J Gastroenterol Hepatol 19 (2004) 854
31. Teruel T., Hernandez R., Rial E., Martin-Hidalgo A., and Lorenzo M. Rosiglitazone up-regulates lipoprotein lipase, hormone-sensitive lipase and uncoupling protein-1, and down-regulates insulin-induced fatty acid synthase gene expression in brown adipocytes of Wistar rats. Diabetologia 48 (2005) 1180
32. Schadinger S.E., Bucher N.L., Schreiber B.M., and Farmer S.R. PPARgamma2 regulates lipogenesis and lipid accumulation in steatotic hepatocytes. Am J Physiol Endocrinol Metab 288 (2005) E1195
33. Fonseca V. Effect of thiazolidinediones on body weight in patients with diabetes mellitus. Am J Med 115 (2003) 42S
34. Shadid S., and Jensen M.D. Effects of pioglitazone versus diet and exercise on metabolic health and fat distribution in upper body obesity. Diabetes Care 26 (2003) 3148
35. de Souza C.J., Eckhardt M., Gagen K., et al. Effects of pioglitazone on adipose tissue remodeling within the setting of obesity and insulin resistance. Diabetes 50 (2001) 1863
36. Yamagishi S., Nakamura K., Takeuchi M., and Imaizumi T. Molecular mechanism for accelerated atherosclerosis in diabetes and its potential therapeutic intervention. Int J Clin Pharmacol Res 24 (2004) 129
37. Thomas M.C., Forbes J.M., and Cooper M.E. Advanced glycation end products and diabetic nephropathy. Am J Ther 12 (2005) 562
38. Stitt A.W. The role of advanced glycation in the pathogenesis of diabetic retinopathy. Exp Mol Pathol 75 (2003) 95
39. Friedman E.A. Advanced glycosylated end products and hyperglycemia in the pathogenesis of diabetic complications. Diabetes Care 22 (1999) B65
40. Mendez-Sanchez N., Cardenas-Vazquez R., Ponciano-Rodriguez G., and Uribe M. Pathophysiology of cholesterol gallstone disease. Arch Med Res 27 (1996) 433
41. Moser A.J., Giurgiu D.I., Morgenstern K.E., Abedin Z.R., Roslyn J.J., and Abedin M.Z. Calmodulin regulation of gallbladder ion transport becomes dysfunctional during gallstone formation in prairie dogs. Dig Dis Sci 45 (2000) 1422
42. Abedin M.Z., Giurgiu D.I., Abedin Z.R., Peck E.A., Su X., and Smith P.R. Characterization of NA+/H+ exchanger isoform (NHE1, NH32 and NHE3) expression in prairie dog gallbladder. J Membr Biol 182 (2001) 123
43. Narins S.C., Ramakrishnan R., Park E.H., Smith P.R., Meyers W.C., and Abedin M.Z. Gallbladder Na+/H+ exchange activity is up-regulated prior to cholesterol crystal formation. Eur J Clin Invest 35 (2005) 514
44. Jones R.S., Putnam W., Andersen D.K., Hanks J.B., and Lebovitz H.E. Insulin's effect on bile flow and lipid excretion during euglycemia and hypoglycemia. Dig Dis Sci 29 (1984) 33
45. Banday A.A., Siddiqui A.H., Menezes M.M., and Hussain T. Insulin treatment enhances AT1 receptor function in OK cells. Am J Physiol Renal Physiol 288 (2005) F1213
46. Fujioka Y., Masai M., Tsuboi S., et al. Troglitazone reduces activity of the Na+/H+ exchanger in fructose-fed borderline hypertensive rats. Hypertens Res 26 (2003) 111